TSGΔ154-1054 splice variant increases TSG101 oncogenicity by inhibiting its E3-ligase-mediated proteasomal...

Area of Science:

• Molecular Biology
• Cancer Biology
• Biochemistry

Background:

• Tumor Susceptibility Gene 101 (TSG101) is crucial for cell division and trafficking, and its aberrant expression is linked to human cancers.
• A specific TSG101 splicing variant, TSGΔ154-1054, correlates with advanced tumor stages and metastasis.
• TSG101 protein levels are regulated by proteasomal degradation pathways involving Tal and MDM2.

Purpose of the Study:

• To elucidate the mechanism by which the TSGΔ154-1054 variant contributes to cancer progression.
• To investigate the interaction between TSGΔ154-1054, TSG101, and their regulatory proteins (Tal and MDM2).
• To determine the functional impact of TSGΔ154-1054 on TSG101 stability and cancer-associated phenotypes.

Main Methods:

• Investigated protein-protein interactions using co-immunoprecipitation assays.
• Analyzed the effect of TSGΔ154-1054 on TSG101 ubiquitination and degradation.
• Assessed the impact of TSGΔ154-1054 on cell proliferation, clonogenicity, and tumor growth in vivo.

Main Results:

• The TSGΔ154-1054 variant stabilizes TSG101 protein by competitively binding to Tal, inhibiting TSG101 polyubiquitination and proteasomal degradation.
• This stabilization specifically enhances TSG101-driven cell proliferation, clonogenicity, and tumor growth in mouse models.
• MDM2-mediated degradation pathway is not affected by the TSGΔ154-1054 variant.

Conclusions:

• TSGΔ154-1054 prevents the ubiquitin-proteasome system from degrading TSG101, thereby increasing tumor malignancy.
• The findings highlight the functional importance of TSGΔ154-1054 in cancer progression.
• TSGΔ154-1054 represents a potential therapeutic target for various human cancers.